Ensign Peak Advisors
BSX icon

Ensign Peak Advisors’s Boston Scientific BSX Stock Holding History

Ensign Peak Advisors’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251M Buy
5,881,367
+1,374,125
+30% +$74.6M 0.41% 44
2026
Q1 		$283M Buy
4,507,242
+2,929,480
+186% +$234M 0.53% 33
2025
Q4 		$150M Buy
1,577,762
+102,272
+7% +$10M 0.27% 77
2025
Q3 		$144M Buy
1,475,490
+224,012
+18% +$23.2M 0.24% 86
2025
Q2 		$134M Buy
1,251,478
+277,317
+28% +$28.1M 0.23% 90
2025
Q1 		$98.3M Sell
974,161
-561,778
-37% -$56.6M 0.19% 116
2024
Q4 		$137M Sell
1,535,939
-147,058
-9% -$12.9M 0.24% 80
2024
Q3 		$141M Sell
1,682,997
-164,395
-9% -$13M 0.25% 81
2024
Q2 		$142M Sell
1,847,392
-380,423
-17% -$27.8M 0.26% 77
2024
Q1 		$153M Buy
2,227,815
+294,081
+15% +$18.9M 0.28% 71
2023
Q4 		$112M Buy
1,933,734
+74,773
+4% +$3.99M 0.22% 98
2023
Q3 		$98.2M Buy
1,858,961
+401,718
+28% +$21.1M 0.21% 100
2023
Q2 		$78.8M Sell
1,457,243
-206,574
-12% -$10.8M 0.16% 119
2023
Q1 		$83.2M Sell
1,663,817
-175,908
-10% -$8.29M 0.18% 114
2022
Q4 		$85.1M Buy
1,839,725
+42,379
+2% +$1.84M 0.19% 114
2022
Q3 		$69.6M Sell
1,797,346
-144,633
-7% -$5.8M 0.17% 116
2022
Q2 		$72.4M Buy
1,941,979
+84,173
+5% +$3.43M 0.17% 117
2022
Q1 		$82.3M Sell
1,857,806
-64,901
-3% -$2.81M 0.17% 118
2021
Q4 		$81.7M Buy
1,922,707
+84,414
+5% +$3.55M 0.16% 132
2021
Q3 		$79.8M Buy
1,838,293
+659,331
+56% +$29.2M 0.17% 129
2021
Q2 		$50.4M Sell
1,178,962
-12,136
-1% -$511K 0.1% 176
2021
Q1 		$46M Buy
1,191,098
+114,288
+11% +$4.33M 0.1% 183
2020
Q4 		$38.7M Buy
1,076,810
+846,454
+367% +$30.5M 0.09% 201
2020
Q3 		$8.8M Buy
230,356
+28,933
+14% +$1.11M 0.02% 470
2020
Q2 		$7.07M Sell
201,423
-53,010
-21% -$1.91M 0.02% 504
2020
Q1 		$8.3M Sell
254,433
-254,149
-50% -$9.93M 0.03% 389
2019
Q4 		$23M Buy
+508,582
New +$21.3M 0.06% 265

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ensign Peak Advisors's BSX Position: Q2 2026 in Review

Ensign Peak Advisors increased its Boston Scientific (BSX) stake by 30% in Q2 2026, buying an estimated $74.6M and bringing the position to 5,881,367 shares worth $251M. The position accounts for 0.41% of the portfolio, ranked #44.

Ensign Peak Advisors first reported a position in BSX in Q4 2019 and has held it in 27 quarters since. The position peaked at $283M in Q1 2026. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Ensign Peak Advisors held 5,881,367 shares of Boston Scientific worth $251M as of Q2 2026.
  • Ensign Peak Advisors bought 1,374,125 Boston Scientific shares in Q2 2026, an estimated $74.6M.
  • Boston Scientific made up 0.41% of Ensign Peak Advisors's portfolio in Q2 2026, its #44 holding.
  • Ensign Peak Advisors first reported a position in Boston Scientific in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's Boston Scientific position peaked at $283M in Q1 2026.
  • 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.